BSX vs. MCK: Boston Scientific vs. McKesson Stock Comparison

Company Profile

Boston Scientific (BSX) and McKesson (MCK) both fall under the Health Care Equipment & Services industry group, but BSX is classified in Health Care Equipment & Supplies while MCK is classified in Health Care Providers & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Boston Scientific (BSX) is heavily traded at around 19.73M shares per day, whereas McKesson (MCK) sees a more moderate 822.69K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Boston Scientific (BSX) earns 14.12% on shareholders’ equity, ranked against its industry; McKesson (MCK) has no ROE this period.

Boston Scientific (BSX) at 16.62% retains a top-quartile share of revenue as profit, ahead of McKesson (MCK) at 1.12%, which keeps about the industry-typical share.

Boston Scientific (BSX) at 19.05% operates in the top operating margin quartile, ahead of McKesson (MCK) at 1.48%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Boston Scientific (BSX) at 19.87% and McKesson (MCK) at 12.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Boston Scientific (BSX) at 55.20% and McKesson (MCK) at 49.22% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

Both Boston Scientific (BSX) at 1.37 and McKesson (MCK) at 0.90 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Only one side’s leverage can be read here: Boston Scientific (BSX) carries debt-to-equity ratio of 0.46 against its industry range, while McKesson (MCK) reports no figure this period.

Financial Strength Metrics

Dividends

Boston Scientific (BSX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile McKesson (MCK) reports a yield of 0.32%, ranking against industry peers normally.

Boston Scientific (BSX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile McKesson (MCK) reports a payout of 8.77%, ranking against industry peers normally.

Dividend Metrics

Valuation

Boston Scientific (BSX) at 18.04 sits in the cheaper P/E ratio quartile, while McKesson (MCK) at 27.36 is closer to its industry’s usual earnings multiple — a discount for BSX, though growth and earnings durability still matter.

McKesson (MCK) at 0.29 sits in the cheaper P/S ratio quartile while Boston Scientific (BSX) at 2.94 prices around its industry’s middle — MCK costs less per dollar of sales, though read it alongside growth and margins.

McKesson (MCK) reports a negative P/B ratio of -30.85, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Boston Scientific (BSX) reports 2.42, ranking against industry peers normally.

Valuation Metrics